Comprehensive genomic profiling (CGP) illumina.com/areas-of-interest/cancer/clinical-cancer-research/cgp.html
assesses hundreds of tumor genes to find actionable mutations and is becoming the standard of care for many cancers. However, oncologists often opt for single-gene tests (SGT) before pursuing CGP. A recent study meetings.asco.org/abstracts-presentations/219900, conducted by Labcorp and presented at the recent American Society of Clinical Oncology (ASCO) meetings.asco.org/meetings/2023-asco-annual-meeting/299/program-guide/scheduled-sessions Annual Meeting, showed that SGTs use up precious biopsy samples, reducing CGP effectiveness and depriving patients of comprehensive genomic information about their tumors. Illumina Chief Medical Officer Phil Febbo discussed this study with Dr. Vivek Subbiah, MD, now chief of Early-Phase Drug Development at Sarah Cannon Research Institute and Dr. Prasanth Reddy, a medical oncologist. Read more about Illumina and CGP here: illumina.com/company/news-center/feature-articles/new-research-shows-comprehensive-genomic-profiling-is-most-effec.html
Subscribe to the Illumina video channel youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. View customer spotlight videos youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina product videos youtube.com/playlist?list=PLKRu7cmBQlaj6YuZmkfxZcT9twqDgP2Xd View Illumina support videos youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM Facebook: facebook.com/illuminainc LinkedIn: linkedin.com/company/illumina Instagram: instagram.com/illuminainc Twitter: twitter.com/illumina #CGP #Precisionmedicine #Comprehensivegenomicprofiling #Tumorprofiling #Tumorbiomarkers #TumorNGStesting #Cancerpanel #Cancerbiomarkerpanel #Personalizedmedicine